02/22/2019 | Press release | Distributed by Public on 02/22/2019 06:53
TORONTO, CANADA - (February 22, 2019) - Antibe Therapeutics Inc. ('Antibe' or the 'Company') (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has been named a 2019 TSX Venture 50™ company, an award that recognizes the top performing companies on the TSX Venture Exchange over the past year. Antibe was ranked second in the Clean Technology and Life Sciences sector.
The TSX Venture 50™ is a ranking of the top ten performers on TSX Venture Exchange from each of five industry sectors: Clean Technology and Life Sciences, Diversified Industries, Energy, Mining, and Technology. The 2019 Venture 50™ winners were selected based on market capitalization growth, share price appreciation and trading volume for the 2018 calendar year.
'We are honoured to be recognized as a top performer on the TSX Venture Exchange, which reflects the best-in-class potential of our pipeline of novel hydrogen sulfide-releasing NSAIDs,' commented Dan Legault, Antibe's CEO. 'We hope to continue this success for our shareholders in 2019 as we look to fully validate the effectiveness of our lead drug, ATB-346, in the recently commenced Phase 2B dose-ranging, efficacy study.'
For more information on the TSX Venture 50™, including the ranking and list of this year's winners, please visit: www.tsxventure50.com.
Antibe's subsidiary, Citagenix Inc. ('Citagenix'), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions 'will', 'anticipate', 'believe', 'plan', 'estimate', 'expect', 'intend', 'propose' and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company's ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law. Antibe Therapeutics Inc. Dan Legault Chief Executive Officer Tel: +1 416-473-4095